Janux presents preclinical data for JANX007 and JANX008 at PEGS Boston conference

Janux Therapeutics, Inc.

Management presented two posters at PEGS Boston on May 2-5, 2022.
JANX007 is a PSMA-targeted TRACTr for prostate cancer; JANX008 is EGFR-targeted for solid tumors.
Data is preclinical; no clinical results or financial guidance disclosed.

item 8.01 item 9.01

Janux Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-006779

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.